mean_indean
Posted - 1 week ago
$MCRB $SGTX (Sigilon) got down to a split adjusted (12:1) price of .31 before the buyout. Patience.
Chiasma
Posted - 03/28/24
$HEPA I envision a deal very similar to $SGTX I see them perhaps releasing some data early to give a glimpse, this runs to $20/share, we get a deal for $30/share and then it becomes structured. $50/share with completion of phase IIb, $50/share with completion of phase III, and $50/share with PDUFA acceptance. https://www.fiercebiotech.com/biotech/lilly-raiding-biotech-bargain-bin-buys-diabetes-cell-therapy-partner-sigilon-35m
Who_is_JohnnyGalt
Posted - 1 month ago
$MCRB $SGTX True but SGTX also did a 1 for 13 rss on May 23, 2023.
SwordfishTrader
Posted - 1 month ago
$MCRB $SGTX useful analogy and reminder. See the forest through the trees and have patience if you are sure of the VALUE here. Numbers don’t lie and math adds up.
mean_indean
Posted - 1 month ago
$MCRB Sigilon therapeutics $SGTX 2/28/23 - exec team given shares ($15 sp)
6/28/23 - price hits $3.82
6/29/23 - price hits $28 after Eli Lilly Acquisition Seres therapeutics
2/16/24 - exec team given shares ($1.06 sp)
…..
…..
trf07
Posted - 1 month ago
$CELZ Know what you hold. $PRVB was into T1 Diabetes therapy also and was bought at 2.9 billion $. $SGTX also early stage T1 Diabetes therapy was bought for more than 300 milliy$. CELZ mcap currently 9 mill. 😎
EddieH2020
Posted - 3 months ago
$EFTR Fun fact:
$SGTX did a 1 for 13 reverse split on 5/23/23, only to get bought out by $LLY with buyout news hitting less than 6 weeks after.
You really just never know 🤷🏼♂️
GSMITH10107
Posted - 3 months ago
@Kremm not for biotechs - see $VTGN $CRIS $ORTX $SGTX ALL up multiples since reverse split just depends on managements intentions IMO
GSMITH10107
Posted - 3 months ago
$EFTR alot of biotechs reverse split names that have done extremely well post RS I think its not viewed as it used to be especially with amazing management. ($EFTR management team is great) think $HARP $SGTX $CRIS all doing amazing post reverse split however my personal investment thesis relies on 2024 and the data that is released selling pressure might subside especially when there isn't 75 million shares floating around
GSMITH10107
Posted - 3 months ago
$EFTR knew they would RS but not worried as $SGTX got bought out for a huge premium after RS AND $HARP
barkemylou
Posted - 12/30/23
@RMcCourt600 It is all about making money my friend. That was a small profit. $CING $SGTX $CGA much better
BiotechValues
Posted - 4 months ago
@Odintrading @RallyRaider correct. And a R/S means nothing. $SGTX did a 1:13 R/S, dropped shares to 2.5M O/S, and was bought out by its partner Lilly a month after.
Chief_EZ
Posted - 6 months ago
$FNCH imagine waking up one day to a buyout of $15 a share like $SGTX
RallyRaider
Posted - 6 months ago
$SRZN If you believe in positive data or any partnerships or M&A action, there will be bidders leaving the table and thus suppressing price before the actual event happens. look at the charts of the recent fancy names out there $TPST $SLNO $SGTX
Day3
Posted - 6 months ago
$UBX I think they are about to be bought out. Why would they pay off a $16m loan early when they didn't need to? $SGTX did same and Lilly bought them out 38 days after they paid off their loan. UBX once valued at $300m, now sitting at $30m valuation with $70m cash and reasonable burn rate. DME market is in the billions and this is the cheapest drug to buy with comparable efficacy to Eylea. UBX won't have/be able to raise the funds to take this all the way and a bigger player would rather buy it on the cheap rather than partner up. Also, bigger player can focus future trials on a more unmet need area rather than compete with Eylea et al. A lot of money has already been spent derisking UBX-1325 so makes it an ideal product to buy on the cheap.
A $5-6 per share upfront offer with tasty, achievable tiered CVRs should do the trick. All speculation on my part, but makes total sense to me. If a buy-out happens, I'm betting on October.
BioCEOsSukk
Posted - 09/29/23
So $LLY bought $SGTX for 381 percent of the share price plus CVRs for about 10x that.
For $OPGN, the cash part at today's closing price would be around 1.53 - and they could do a $7.50 CVR for UTI approval each in USA and China.
If you're watching Yvonne - this is your blueprint to finish the deal this weekend...
SmallCapManager
Posted - 09/28/23
@Joefallin @Alexii Pretty sure I was correct on $CABA, $SGTX, $STSA and others but keep nitpicking ones that haven’t materialized yet my number 1 fan! It also gives me pleasure to stay in your head rent free. Cheers 🍻
IDKstocksanymore
Posted - 7 months ago
$SGTX what happened to this stock, cannot find the ticker to trade
Gohan89
Posted - 7 months ago
$SGTX up almost 200 percent in a year. Did this rs? Or just good news?
randy212
Posted - 7 months ago
@BullFisher00 I can see you are a long time Investor so you know better but you may want to look at $SGTX after r/s. Something definetly cooking here with huge volume.
zedma
Posted - 8 months ago
@MBA_Certified and same with $SGTX, some losers like you were crying that Lilly is overpaying,🤣😂🤣😂
biostock
Posted - 8 months ago
$CELZ When stock is range bound and getting impatient just read the $LLY deal for $SGTX . Whole bio sector is in the shorts clutches for now but when it takes off i expect it to make it up big time. My guesstimate is BPs are awaiting green light for flurry of deals across the sector.
Tha_D
Posted - 8 months ago
$SGTX getting out
cctranscripts
Posted - 8 months ago
Securities registration termination [Section 12(g)] https://www.conferencecalltranscripts.org/summary/?id=12473944 $SGTX
Quantisnow
Posted - 8 months ago
$SGTX 📜 SEC Form 15-12G filed by Sigilon Therapeutics Inc.
https://quantisnow.com/i/4920153?utm_source=stocktwits
45 seconds delayed.
DonPeriyon
Posted - 8 months ago
$SGTX stay away from this garbage of a company, this company would have been bought out while it was trading for pennies on the dollar, how convenient it was to steal away our shares on a dirty reverse split to then have Lily bought everything up once the split was completed. It will be more of the rinse and repeat at a higher cost of course only for the retail investor to get screw. Why force us to sell at $14 when we could have decided to sell much higher?!?!? I will not buy into this garbage company again.
PercyFinn
Posted - 8 months ago
$SGTX I've sold all my SGTX stock on the 10th of August just one day before the closing day for a very simple reason. I did not want to hold any CVRs because I believe LLY bought out SGTX to kill their research and promising results. All of it lays now in a safe place and allows LLY to continue selling insulin as it will continue to provide them with a steady stream of revenue for years to come if not decades. After all, as we all know, for any Big Pharma co. treating any kind of sickness at it's root cause doesn't make any financial sense. Tylenol, anybody? Keep your CVRs. To me it's just hoping for a miracle.
macroaxis
Posted - 8 months ago
$SGTX - Next fiscal quarter end is on 30th of September 2023. Strong transformation in Median Price detected https://www.macroaxis.com/stocks/Price-Transform/Median-Price/SGTX
seforim
Posted - 8 months ago
@DoctrBenway @Watson66 just trying to be realistic :) look at the $SGTX b/o
